|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kew MC: Hepatocellular carcinoma:
Epidemiology and risk factors. J Hepatocell Carcinoma. 1:115–125.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perz JF, Armstrong GL, Farrington LA,
Hutin YJ and Bell BP: The contributions of hepatitis B virus and
hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kanneganti T: Central roles of NLRs and
inflammasomes in viral infection. Nat Rev Immunol. 10:688–698.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen W, Xu Y, Li H, Tao W, Xiang Y, Huang
B, Niu J, Zhong J and Meng G: HCV genomic RNA activates the NLRP3
inflammasome in human myeloid cells. PLoS One. 9:e849532014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Szabo G and Petrasek J: Inflammasome
activation and function in liver disease. Nat Rev Gastro Hepat.
12:387–400. 2015. View Article : Google Scholar
|
|
8
|
Franchi L, Eigenbrod T, Muñoz-Planillo R
and Nuñez G: The inflammasome: A caspase-1-activation platform that
regulates immune responses and disease pathogenesis. Nat Immunol.
10:241–247. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wree A, Eguchi A, Mcgeough MD, Pena CA,
Johnson CD, Canbay A, Hoffman HM and Feldstein AE: NLRP3
inflammasome activation results in hepatocyte pyroptosis, liver
inflammation, and fibrosis in mice. Hepatology. 59:898–910. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aachoui Y, Sagulenko V, Miao EA and Stacey
KJ: Inflammasome-mediated pyroptotic and apoptotic cell death, and
defense against infection. Curr Opin Microbiol. 16:319–326. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bauernfeind F, Rieger A, Schildberg FA,
Knolle PA, Schmid-Burgk JL and Hornung V: NLRP3 inflammasome
activity is negatively controlled by miR-223. J Immunol.
189:4175–4181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ramkissoon SH, Mainwaring LA, Ogasawara Y,
Keyvanfar K, McCoy JP Jr, Sloand EM, Kajigaya S and Young NS:
Hematopoietic-specific microRNA expression in human cells. Leuk
Res. 30:643–647. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wong QW, Lung RW, Law PT, Lai PB, Chan KY,
To KF and Wong N: MicroRNA-223 is commonly repressed in
hepatocellular carcinoma and potentiatesexpression of stathmin1.
Gastroenterology. 135:257–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Allen IC, Tekippe EM, Woodford RM, Uronis
JM, Holl EK, Rogers AB, Herfarth HH, Jobin C and Ting JP: The NLRP3
inflammasome functions as a negative regulator of tumorigenesis
during colitis-associated cancer. J Exp Med. 207:1045–1056. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ghiringhelli F, Apetoh L, Tesniere A,
Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G,
Ullrich E, et al: Activation of the NLRP3 inflammasome in dendritic
cells induces IL-1beta-dependent adaptive immunity against tumors.
Nat Med. 15:1170–1178. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bruchard M, Mignot G, Derangère V, Chalmin
F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL,
et al: Chemotherapy-triggered cathepsin B release in
myeloid-derived suppressor cells activates the Nlrp3 inflammasome
and promotes tumor growth. Nat Med. 19:57–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dupaul-Chicoine J, Arabzadeh A, Dagenais
M, Douglas T, Champagne C, Morizot A, Rodrigue-Gervais IG, Breton
V, Colpitts SL, Beauchemin N and Saleh M: The Nlrp3 inflammasome
suppresses colorectal cancer metastatic growth in the liver by
promoting natural killer cell tumoricidal activity. Immunity.
43:751–763. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wei Q, Mu K, Li T, Zhang Y, Yang Z, Jia X,
Zhao W, Huai W, Guo P and Han L: Deregulation of the NLRP3
inflammasome in hepatic parenchymal cells during liver cancer
progression. Lab Invest. 94:52–62. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei Q, Guo P, Mu K, Zhang Y, Zhao W, Huai
W, Qiu Y, Li T, Ma X, Liu Y, et al: Estrogen suppresses
hepatocellular carcinoma cells through ERβ-mediated upregulation of
the NLRP3 inflammasome. Lab Invest. 95:804–816. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen K, Mi MT and Yu XP: Effects of
taurine on apoptosis of photoreceptors and NF-kB/Caspase-1 pathway
in photochemical damage. Acta Nutrimenta Sinica. 8:296–299.
2006.(In Chinese).
|
|
24
|
Yang N, Ekanem NR, Sakyi CA and Ray SD:
Hepatocellular carcinoma and microRNA: New perspectives on
therapeutics and diagnostics. Adv Drug Deliv Rev. 81:62–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Haneklaus M, Gerlic M, Kurowska Stolarska
M, Rainey AA, Pich D, Mcinnes IB, Hammerschmidt W, Neill LA and
Masters SL: Cutting edge: miR-223 and EBV miR-BART15 regulate the
NLRP3 inflammasome and IL-1β production. J Immunol. 189:3795–3799.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nian W, Ao X, Wu Y, Huang Y, Shao J, Wang
Y, Chen Z, Chen F and Wang D: miR-223 functions as a potent tumor
suppressor of the Lewis lung carcinoma cell line by targeting
insulin-like growth factor-1 receptor and cyclin-dependent kinase
2. Oncol Lett. 6:359–366. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao
QL, Wu W and Wu XZ: MiR-223 suppresses cell proliferation by
targeting IGF-1R. PLoS One. 6:e270082011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li G, Cai M, Fu D, Chen K, Sun M, Cai Z
and Cheng B: Heat shock protein 90B1 plays an oncogenic role and is
a target of microRNA-223 in human osteosarcoma. Cell Physiol
Bioche. 30:1481–1490. 2012. View Article : Google Scholar
|
|
29
|
Li S, Li Z, Guo F, Qin X, Liu B, Lei Z,
Song Z, Sun L, Zhang HT, You J and Zhou Q: miR-223 regulates
migration and invasion by targeting Artemin in human esophageal
carcinoma. J Biomed Sci. 18:242011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li X, Zhang Y, Zhang H, Liu X, Gong T, Li
M, Sun L, Ji G, Shi Y, Han Z, et al: miRNA-223 promotes gastric
cancer invasion and metastasis by targeting tumor suppressor
EPB41L3. Mol Cancer Res. 9:824–833. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu L, Li H, Jia CY, Cheng W, Yu M, Peng M,
Zhu Y, Zhao Q, Dong YW, Shao K, et al: MicroRNA-223 regulates FOXO1
expression and cell proliferation. FEBS Lett. 586:1038–1043. 2012.
View Article : Google Scholar : PubMed/NCBI
|
